Journal DOI 10.68956/journal.human-performance-futures

Creative Commons source reading · Musculoskeletal and tissue health

Patient‐reported outcomes after anterior cruciate ligament reconstruction with the JewelACL synthetic ligament: Multicenter study of at least 9 years follow‐up

Klaudiusz Kosowski; Ewa Bręborowicz; Marek Olek; Maciej Wiśniewski

Originally published in J Exp Orthop · 2026-07-01

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

AbstractPurposeSynthetic grafts for anterior cruciate ligament (ACL) reconstruction aim to address limitations of biological grafts, such as donor‐site morbidity and delayed recovery. JewelACL is a synthetic scaffold developed to enhance biological integration and mechanical durability. This multicenter study evaluated long‐term patient‐reported outcomes, adverse events, re‐rupture rates and return‐to‐sport outcomes following ACL reconstruction using JewelACL, with a minimum follow‐up of 9 years.MethodsA retrospective cohort of 58 patients who underwent ACL reconstruction between 2010 and 2014, using either JewelACL alone (n = 44) or JewelACL combined with hamstring autograft (hybrid technique; n = 14), was assessed. Patient‐reported outcome measures (PROMs), including the International Knee Documentation Committee (IKDC), Lysholm and…

RESULTS

Follow‐up time from surgery was summarised for the overall cohort (N = 58) and by treatment subgroup. Mean ± SD follow‐up was 10.8 ± 0.9 years (range 9.0–12.6) in the full cohort, 10.8 ± 0.9 years (range 9.0–12.6) in the JewelACL‐only group (N = 44) and 10.8 ± 0.9 years (range 9.1–12.3) in the JewelACL + autograft (hybrid) group (N = 14). Overall, the mean follow‐up was approximately 11 years, and all patients had at least 9 years of follow‐up (minimum 9.0 years). Primary efficacy analysis. Re‐rupture data (Table 2) were available for all 58 patients at long‐term follow‐up (≥ 9 years). Overall, three patients experienced a re‐rupture (5.2%), with a 95% CI indicating that the underlying proportion could be as high as 14.4%. All re‐ruptures occurred in the JewelACL‐only group (3/44; 6.8%), whereas no re‐ruptures were reported in the…

DISCUSSION

The most important findings of the present study are the low re‐rupture rate, favourable functional outcomes and high percentage of patients returning to sport [20]. The re‐rupture rate for all study participants receiving the JewelACL device for ACL reconstruction was 5.2% at a mean follow‐up of 10.8 ± 0.9 years (6.8% and 0.0% in the JewelACL only group and the JewelACL hybrid group, respectively). Rupture occurred between 9 and 10 years postsurgery, most commonly during football or after a slip injury. Re‐rupture rates of between 0% and 30% at a minimum follow‐up of 2 years have been reported in state‐of‐the‐art literature for ACL reconstruction using autografts and allografts; [9, 10, 23] one study [31] reported a rate of 6.2% at more than 9 years follow‐up in 2700 implants. For the ligament advanced reinforcement system (LARS), a…

Editorial reading guide

  • How were injury, recovery and exposure defined and verified?
  • Which criteria support progression, and what finding should stop or change the plan?